company_name = Sanofi-Aventis
company_type = Public (
Euronext[http://www.euronext.com/trader/summarizedmarket/0,5372,1732_6834,00.html?selectedMep=1&idInstrument=20812&isinCode=FR0000120578 SAN] , NYSE, LSE and FWB)
company_slogan = Because health matters. (French: "L'essentiel c'est la santé.")
August 20, 2004"by acquisition"
key_people = Jean-François Dehecq "Chairman" Gérard Le Fur "CEO"
industry = Pharmaceutical
num_employees = 100,000 (2007)
products = Lovenox®/Clexane® Thrombosis
Lantus® Diabetes Taxotere® Breast Cancer, Lung Cancer, Prostate Cancer
Eloxatine® Colorectal Cancer
Stilnox®/Ambien®/Ambien CR®/Myslee® Zolfresh Zolt Stilnoct Nimadorm Hypnogen Zodorm Stella Sanval Zoldorm Nitrest Silence Your Rooster Insomnia Copaxone® Multiple Sclerosis
Aprovel®/Avapro®/Karvea® Hypertension Delix®/Tritace®/Triatec® Hypertension Allegra®/Telfast® Allergic Rhinitis Menactra Meningitis disease Xatral® Benign Prostate Hypertrophia Actonel® Osteoporosis, Paget’s Disease Dépakine® Epilepsy Nasacort® Allergic Rhinitis
revenue = )
homepage = [http://en.sanofi-aventis.com/ en.sanofi-aventis.com]
Sanofi-Aventis (Euronext|SAN, NYSE|SNY), headquartered in
Paris, France, is a multinational pharmaceutical company. The company is the world's fourth largest pharmaceutical company. Sanofi-Aventis engages in the research, development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but they also develop over-the-counter medication. Sanofi-Aventis cover 7 major therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicineand vaccines(with its subsidiary Sanofi Pasteur).
Sanofi-Aventis is a full member of the
European Federation of Pharmaceutical Industries and Associations(EFPIA). [cite news|url=http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883|title=The Pharmaceutical Industry in Figures - 2008 Edition |publisher=European Federation of Pharmaceutical Industries and Associations (EFPIA)|pages=49|language=english|accessdate=2008-08-25]
Sanofi Aventis was formed in 2004 when
Sanofi-Synthélaboacquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of $54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.
Sanofi-Synthélabowas formed in 1999 when Sanofi(former subsidiary of Total) merged with Synthélabo(former subsidiary of L'Oréal). The merged company was based in Paris, France.
The Canadian operations of Sanofi-Aventis began as Connaught Laboratories/Connaught Medical Research Laboratories of the
University of Torontofrom 1914 to 1972. It was purchased by federal government's Canadian Development Corporationand later privatized. Sold to the French Institut Mérieuxin 1989 and renamed Pasteur Merieux Connaught. A series of mergers would follow and the Canada unit was renamed Connaught Campus" of Aventis Pasteur. It is now the Canadianunit of Sanofi Pasteurand part of the Sanofi-Aventisempire.
Aventis was formed in 1999 when
Rhône-PoulencS.A. merged with Hoechst Marion Roussel, which itself was formed from the merger of Hoechst AGwith Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.
* Jean-François Dehecq, Chairman
* Gérard Le Fur,
CEODehecq has been the General Manager of Sanofi since its creation in 1973.
[http://sec.edgar-online.com/2008/03/07/0001193125-08-049502/Section12.asp Stockholders, Sanofi-aventis ownership structure as of February 29, 2008]
* Breakdown of share ownership: 12.64% by Total, 8.65% by
L'Oréal, 3.07% treasury shares, 1.24% employees, the remaining 70.40% are publicly traded.
* Voting rights distribution: 19.55% to Total, 14.72% to L'Oréal, 1.98% to employees, and 63.75% to the public.
[http://www.drugs.com/news/sanofi-aventis-2007-fourth-quarter-full-year-net-sales-7752.html From Drugs.com]
- 28 billion euros= Consolidated net sales 2007
- 4,537 M euros = R&D expenditure representing 16.2 % of net sales
- Nearly 100,000 employees
The Aventis Foundation, a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc. The foundation was responsible for sponsoring the Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, and which have grown to be one of the world's most prestigious non-fiction literary prizes. In 2006, the foundation severed its connection with the prizes and from 2007 they have been known as the
Royal Society Prizes for Science Booksand are managed by the Royal Society, the UK national academy of science.
* [http://finance.yahoo.com/q/pr?s=SNY Yahoo! Finance - Sanofi-Aventis Company Profile]
In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the
InnoMed PredTox. [Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [http://www.ncbi.nlm.nih.gov/pubmed/18449490] ] cite web|url=http://www.innomed-predtox.com/consortium/members/|title=InnoMed PredTox Member Organizations|accessdate=2008-08-25] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiativeof EFPIAand the European Commission.cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|accessdate=2008-08-25]
* [http://en.sanofi-aventis.com/ Official site]
* [http://www.aventis-foundation.org/ Aventis Foundation]
* [http://www.sanofipasteur.com sanofi pasteur - The vaccines business of sanofi-aventis Group]
Wikimedia Foundation. 2010.
Look at other dictionaries:
Sanofi-Aventis — Logo de sanofi aventis Création 20 août 2004 … Wikipédia en Français
Sanofi Aventis — Logo de sanofi aventis Création 20 août 2004 … Wikipédia en Français
Sanofi-Aventis — Sanofi Rechtsform Société Anonyme ISIN FR0000120578 Gründung … Deutsch Wikipedia
Sanofi-Aventis — Тип Публичная компания Листинг на бирже … Википедия
Sanofi-aventis — Groupe Unternehmensform Société Anonyme ISIN … Deutsch Wikipedia
Sanofi-aventis SA — Sanofi aventis Groupe Unternehmensform Société Anonyme ISIN … Deutsch Wikipedia
Sanofi Aventis — Groupe Unternehmensform Société Anonyme ISIN … Deutsch Wikipedia
Sanofi-Aventis — es un grupo farmacéutico europeo nacido en 2004 de la fusión de la francesa Sanofi Synthélabo y la franco alemana Aventis (que fue el resultado de la fusión de la empresa alemana Hoechst y la francesa Rhône Poulenc). Sanofi Aventis es una de las… … Wikipedia Español
Sanofi-Aventis — ▪ French company French pharmaceutical company founded in 2004 through the merger of Sanofi Synthélabo SA and a much larger French firm, Aventis. Primarily focused on the development and sale of prescription medications, Sanofi Aventis is… … Universalium
Sanofi-Aventis — ► Grupo nacido en 2004 tras la fusión de Sanofi Synthélabo y Aventis, que a su vez procedía de la unión, en 1999, de la sociedad francesa Rhône Poulenc y la empresa alemana Hoechst … Enciclopedia Universal